Shares of biotech micro cap Equillium <a href="https://www.marketwatch.com/investing/stock/eq?utm_source=in_materials">soared</a> 33% yesterday, Thursday, February 6, although some of the gains have been lost before the opening bell today. The company <a href="https://www.equilliumbio.com/investors/press-releases/news-details/2025/Equillium-Announces-Positive-Data-from-Phase-2-Study-Evaluating-Itolizumab-in-Patients-with-Moderate-to-Severe-Ulcerative-Colitis/default.aspx?utm_source=in_materials">announced</a> that its drug for ulcerative colitis, which it is testing together with Indian pharmaceutical giant Biocon, has shown results that are no worse than the standard of care for the disease. The therapy is Equillium’s lead candidate to get to market.

Announced successful drug trials boost micro cap Equillium by 33%

Shares of the biotechnology company Equillium, with a market capitalization of $25.7 million, surged over 15% on Tuesday, August 6. The trigger <a href="https://www.equilliumbio.com/investors/press-releases/news-details/2024/Equillium-Announces-Positive-Interim-Analysis-from-Phase-3-EQUATOR-Study-of-Itolizumab-in-Acute-Graft-Versus-Host-Disease/default.aspx">was</a> positive interim results from the trial of its drug for graft-versus-host disease (GvHD), a condition in which a donor's immune cells attack a recipient's body, recognizing it as foreign. Now, Japan’s Ono Pharmaceutical can exercise a call option to purchase the rights to the drug for approximately $35 million.